EP2972365 - METHODS FOR TREATING AND DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 25.09.2020 Database last updated on 24.08.2024 | |
Former | The patent has been granted Status updated on 18.10.2019 | ||
Former | Grant of patent is intended Status updated on 13.06.2019 | ||
Former | Examination is in progress Status updated on 17.08.2018 | Most recent event Tooltip | 08.07.2022 | Lapse of the patent in a contracting state New state(s): MK | published on 10.08.2022 [2022/32] | Applicant(s) | For all designated states Exagen Diagnostics, Inc. 801 University Boulevard, SE Suite 209 Albuquerque, NM 87106 / US | [2016/03] | Inventor(s) | 01 /
DERVIEUX, Thierry 3009 Caminito Arenoso San Diego, CA 92117 / US | 02 /
BARKEN, Derren 11271 Corte Playa Corona San Diego, CA 92124-4134 / US | [2019/47] |
Former [2016/03] | 01 /
DERVIEUX, Thierry 3009 Caminito Arenoso San Diego, CA 92117 / US | ||
02 /
BARKEN, Derren 1261 Liberty Way Vista, CA 92081 / US | Representative(s) | Zwicker, Jörk ZSP Patentanwälte PartG mbB Hansastraße 32 80686 München / DE | [2019/47] |
Former [2016/03] | Zwicker, Jörk ZSP Patentanwälte Partnerschaftsgesellschaft Radlkoferstrasse 2 81373 München / DE | Application number, filing date | 14720772.4 | 13.03.2014 | [2016/03] | WO2014US25264 | Priority number, date | US201361792284P | 15.03.2013 Original published format: US 201361792284 P | [2016/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014151238 | Date: | 25.09.2014 | Language: | EN | [2014/39] | Type: | A1 Application with search report | No.: | EP2972365 | Date: | 20.01.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.09.2014 takes the place of the publication of the European patent application. | [2016/03] | Type: | B1 Patent specification | No.: | EP2972365 | Date: | 20.11.2019 | Language: | EN | [2019/47] | Search report(s) | International search report - published on: | EP | 25.09.2014 | Classification | IPC: | G01N33/564, G01N33/68 | [2019/14] | CPC: |
G01N33/564 (EP,US);
G01N33/6893 (US);
A61K39/4636 (US);
G01N33/6854 (EP,US);
G01N2333/705 (US);
G01N2800/104 (EP,US);
G01N2800/24 (US);
G01N2800/50 (EP,US);
G01N2800/52 (EP,US);
|
Former IPC [2016/03] | G01N33/564 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/03] | Extension states | BA | Not yet paid | ME | Not yet paid | Title | German: | VERFAHREN ZUR BEHANDLUNG UND DIAGNOSTIZIERUNG VON SYSTEMISCHEM LUPUS ERYTHEMATODES | [2016/03] | English: | METHODS FOR TREATING AND DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS | [2016/03] | French: | MÉTHODES DE TRAITEMENT ET DE DIAGNOSTIC D'UN LUPUS ÉRYTHÉMATEUX DISSÉMINÉ | [2016/03] | Entry into regional phase | 24.08.2015 | National basic fee paid | 24.08.2015 | Designation fee(s) paid | 24.08.2015 | Examination fee paid | Examination procedure | 24.08.2015 | Examination requested [2016/03] | 06.05.2016 | Amendment by applicant (claims and/or description) | 20.08.2018 | Despatch of a communication from the examining division (Time limit: M06) | 20.02.2019 | Reply to a communication from the examining division | 14.06.2019 | Communication of intention to grant the patent | 14.10.2019 | Fee for grant paid | 14.10.2019 | Fee for publishing/printing paid | 14.10.2019 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 20.08.2018 | Opposition(s) | 21.08.2020 | No opposition filed within time limit [2020/44] | Fees paid | Renewal fee | 31.03.2016 | Renewal fee patent year 03 | 27.03.2017 | Renewal fee patent year 04 | 27.03.2018 | Renewal fee patent year 05 | 27.03.2019 | Renewal fee patent year 06 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 13.03.2014 | AL | 20.11.2019 | AT | 20.11.2019 | CY | 20.11.2019 | CZ | 20.11.2019 | DK | 20.11.2019 | EE | 20.11.2019 | ES | 20.11.2019 | FI | 20.11.2019 | HR | 20.11.2019 | IT | 20.11.2019 | LT | 20.11.2019 | LV | 20.11.2019 | MC | 20.11.2019 | MK | 20.11.2019 | MT | 20.11.2019 | NL | 20.11.2019 | PL | 20.11.2019 | RO | 20.11.2019 | RS | 20.11.2019 | SE | 20.11.2019 | SI | 20.11.2019 | SK | 20.11.2019 | SM | 20.11.2019 | TR | 20.11.2019 | BG | 20.02.2020 | NO | 20.02.2020 | GR | 21.02.2020 | IE | 13.03.2020 | LU | 13.03.2020 | IS | 20.03.2020 | BE | 31.03.2020 | PT | 12.04.2020 | [2022/32] |
Former [2022/27] | HU | 13.03.2014 | |
AL | 20.11.2019 | ||
AT | 20.11.2019 | ||
CY | 20.11.2019 | ||
CZ | 20.11.2019 | ||
DK | 20.11.2019 | ||
EE | 20.11.2019 | ||
ES | 20.11.2019 | ||
FI | 20.11.2019 | ||
HR | 20.11.2019 | ||
IT | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
MC | 20.11.2019 | ||
MT | 20.11.2019 | ||
NL | 20.11.2019 | ||
PL | 20.11.2019 | ||
RO | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
SI | 20.11.2019 | ||
SK | 20.11.2019 | ||
SM | 20.11.2019 | ||
TR | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IE | 13.03.2020 | ||
LU | 13.03.2020 | ||
IS | 20.03.2020 | ||
BE | 31.03.2020 | ||
PT | 12.04.2020 | ||
Former [2021/10] | AL | 20.11.2019 | |
AT | 20.11.2019 | ||
CZ | 20.11.2019 | ||
DK | 20.11.2019 | ||
EE | 20.11.2019 | ||
ES | 20.11.2019 | ||
FI | 20.11.2019 | ||
HR | 20.11.2019 | ||
IT | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
MC | 20.11.2019 | ||
NL | 20.11.2019 | ||
PL | 20.11.2019 | ||
RO | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
SI | 20.11.2019 | ||
SK | 20.11.2019 | ||
SM | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IE | 13.03.2020 | ||
LU | 13.03.2020 | ||
IS | 20.03.2020 | ||
BE | 31.03.2020 | ||
PT | 12.04.2020 | ||
Former [2021/08] | AL | 20.11.2019 | |
AT | 20.11.2019 | ||
CZ | 20.11.2019 | ||
DK | 20.11.2019 | ||
EE | 20.11.2019 | ||
ES | 20.11.2019 | ||
FI | 20.11.2019 | ||
HR | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
MC | 20.11.2019 | ||
NL | 20.11.2019 | ||
PL | 20.11.2019 | ||
RO | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
SI | 20.11.2019 | ||
SK | 20.11.2019 | ||
SM | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IE | 13.03.2020 | ||
LU | 13.03.2020 | ||
IS | 20.03.2020 | ||
PT | 12.04.2020 | ||
Former [2021/04] | AL | 20.11.2019 | |
AT | 20.11.2019 | ||
CZ | 20.11.2019 | ||
DK | 20.11.2019 | ||
EE | 20.11.2019 | ||
ES | 20.11.2019 | ||
FI | 20.11.2019 | ||
HR | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
MC | 20.11.2019 | ||
NL | 20.11.2019 | ||
PL | 20.11.2019 | ||
RO | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
SI | 20.11.2019 | ||
SK | 20.11.2019 | ||
SM | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
LU | 13.03.2020 | ||
IS | 20.03.2020 | ||
PT | 12.04.2020 | ||
Former [2020/51] | AL | 20.11.2019 | |
AT | 20.11.2019 | ||
CZ | 20.11.2019 | ||
DK | 20.11.2019 | ||
EE | 20.11.2019 | ||
ES | 20.11.2019 | ||
FI | 20.11.2019 | ||
HR | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
MC | 20.11.2019 | ||
NL | 20.11.2019 | ||
PL | 20.11.2019 | ||
RO | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
SI | 20.11.2019 | ||
SK | 20.11.2019 | ||
SM | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IS | 20.03.2020 | ||
PT | 12.04.2020 | ||
Former [2020/50] | AL | 20.11.2019 | |
AT | 20.11.2019 | ||
CZ | 20.11.2019 | ||
DK | 20.11.2019 | ||
EE | 20.11.2019 | ||
ES | 20.11.2019 | ||
FI | 20.11.2019 | ||
HR | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
MC | 20.11.2019 | ||
NL | 20.11.2019 | ||
RO | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
SI | 20.11.2019 | ||
SK | 20.11.2019 | ||
SM | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IS | 20.03.2020 | ||
PT | 12.04.2020 | ||
Former [2020/37] | AL | 20.11.2019 | |
CZ | 20.11.2019 | ||
DK | 20.11.2019 | ||
EE | 20.11.2019 | ||
ES | 20.11.2019 | ||
FI | 20.11.2019 | ||
HR | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
NL | 20.11.2019 | ||
RO | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
SK | 20.11.2019 | ||
SM | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IS | 20.03.2020 | ||
PT | 12.04.2020 | ||
Former [2020/36] | AL | 20.11.2019 | |
CZ | 20.11.2019 | ||
DK | 20.11.2019 | ||
EE | 20.11.2019 | ||
ES | 20.11.2019 | ||
FI | 20.11.2019 | ||
HR | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
NL | 20.11.2019 | ||
RO | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IS | 20.03.2020 | ||
PT | 12.04.2020 | ||
Former [2020/35] | AL | 20.11.2019 | |
CZ | 20.11.2019 | ||
ES | 20.11.2019 | ||
FI | 20.11.2019 | ||
HR | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
NL | 20.11.2019 | ||
RO | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IS | 20.03.2020 | ||
Former [2020/34] | AL | 20.11.2019 | |
ES | 20.11.2019 | ||
FI | 20.11.2019 | ||
HR | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
NL | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IS | 20.03.2020 | ||
Former [2020/32] | AL | 20.11.2019 | |
FI | 20.11.2019 | ||
HR | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
NL | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IS | 20.03.2020 | ||
Former [2020/26] | FI | 20.11.2019 | |
HR | 20.11.2019 | ||
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
NL | 20.11.2019 | ||
RS | 20.11.2019 | ||
SE | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IS | 20.03.2020 | ||
Former [2020/24] | FI | 20.11.2019 | |
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
NL | 20.11.2019 | ||
SE | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
IS | 20.03.2020 | ||
Former [2020/23] | FI | 20.11.2019 | |
LT | 20.11.2019 | ||
LV | 20.11.2019 | ||
NL | 20.11.2019 | ||
SE | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
GR | 21.02.2020 | ||
Former [2020/22] | FI | 20.11.2019 | |
LT | 20.11.2019 | ||
SE | 20.11.2019 | ||
BG | 20.02.2020 | ||
NO | 20.02.2020 | ||
Former [2020/21] | NO | 20.02.2020 | Cited in | International search | [Y]EP2336769 (HOFFMANN LA ROCHE [CH], et al) [Y] 1-16 * the whole document * * page 27, lines 45-46 * * claim 10 on page 29 * * figure 1 *; | [Y]WO2012109592 (EXAGEN DIAGNOSTICS INC [US], et al) [Y] 1-16 * the whole document *; | [Y] - KENNETH C. KALUNIAN ET AL, "Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus", ARTHRITIS & RHEUMATISM, (20121201), vol. 64, no. 12, doi:10.1002/art.34669, ISSN 0004-3591, pages 4040 - 4047, XP055127913 [Y] 1-16 * the whole document * DOI: http://dx.doi.org/10.1002/art.34669 | [XP] - CHAIM PUTTERMAN, "An Assay Panel Combining Cell Bound Complement Activation Products With Autoantibodies To Extractable Nuclear Antigens and Mutated Citrullinated Vimentin Helps With The Differential Diagnosis Of Systemic Lupus Erythematosus", ARTHRITIS & RHEUMATISM, (20131001), vol. 65, no. S10, ISSN 0004-3591, page S1078, XP055128072 [XP] 1-16 * Abstract 2525 * | [XP] - Chaim Putterman ET AL, "Multicenter study in the AN ASSAY PANEL COMBINING CELL-BOUND COMPLEMENT ACTIVATION PRODUCTS WITH AUTOANTIBODIES TO EXTRACTABLE NUCLEAR ANTIGENS AND MUTATED CITRULLINATED VIMENTIN HELPS WITH THE DIFFERENTIAL DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS", (20131203), URL: http://dfpcorec-p.internal.epo.org/wf/storage/1471FA326FA000134BD/originalPdf, (20140710), XP055128083 [XP] 1-16 * http://avisetest.com/images/stories/publications/sle_2013_acr_poster_final_mktg.pdf * * Poster * | by applicant | - RAHMAN A; ISENBERG DA, "Systemic lupus erythematosus", N ENGL J MED, (2008), vol. 358, no. 9, pages 929 - 939 | - HELMICK CG; FELSON DT; LAWRENCE RC; GABRIEL S; HIRSCH R; KWOH CK ET AL., "Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I", ARTHRITIS RHEUM, (2008), vol. 58, no. 1, pages 15 - 25 | - BASTIAN HM; ROSEMAN JM; MCGWIN G, JR.; ALARCON GS; FRIEDMAN AW; FESSLER BJ ET AL., "Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis", LUPUS, (2002), vol. 11, no. 3, pages 152 - 160 | - TAN EM; COHEN AS; FRIES JF; MASI AT; MCSHANE DJ; ROTHFIELD NF ET AL., "The 1982 revised criteria for the classification of systemic lupus erythematosus", ARTHRITIS RHEUM, (1982), vol. 25, no. 11, pages 1271 - 1277 | - SMITH EL; SHMERLING RH, "The American College of Rheumatology criteria for the classification of systemic lupus erythematosus: strengths, weaknesses, and opportunities for improvement", LUPUS, (1999), vol. 8, no. 8, pages 586 - 595 | - EGNER W, "The use of laboratory tests in the diagnosis of SLE", J CLIN PATHOL, (2000), vol. 53, no. 6, pages 424 - 432 | - MANDERSON AP; BOTTO M; WALPORT MJ, "The role of complement in the development of systemic lupus erythematosus", ANNU REV IMMUNOL, (2004), vol. 22, pages 431 - 456 | - MANZI S; NAVRATIL JS; RUFFING MJ; LIU CC; DANCHENKO N; NILSON SE ET AL., "Measurement of erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus", ARTHRITIS RHEUM, (2004), vol. 50, no. 11, pages 3596 - 3604 | - NAVRATIL JS; MANZI S; KAO AH; KRISHNASWAMI S; LIU CC; RUFFING MJ ET AL., "Platelet C4d is highly specific for systemic lupus erythematosus", ARTHRITIS RHEUM, (2006), vol. 54, no. 2, pages 670 - 674 | - YANG DH; CHANG DM; LAI JH; LIN FH; CHEN CH, "Usefulness of erythrocyte-bound C4d as a biomarker to predict disease activity in patients with systemic lupus erythematosus", RHEUMATOLOGY (OXFORD, (2009), vol. 48, no. 9, pages 1083 - 1087 | - LIU CC; KAO AH; HAWKINS DM; MANZI S; SATTAR A; WILSON N ET AL., "Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus", CLIN TRANSL SCI, (2009), vol. 2, no. 4, pages 300 - 308 | - KAO AH; NAVRATIL JS; RUFFING MJ; LIU CC; HAWKINS D; MC KINNON KM ET AL., "Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus", ARTHRITIS AND RHEUMATISM, (2010), vol. 62, no. 3, pages 837 - 844 | - BATAL I; LIANG K; BASTACKY S; KISS LP; MCHALE T; WILSON NL ET AL., "Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study", LUPUS, (2012), vol. 21, no. I, pages 13 - 26 | - SINGH V; MAHONEY JA; PETRI M, "Erythrocyte C4d and complement receptor 1 in systemic lupus erythematosus", J RHEUMATOL, (2008), vol. 35, no. 10, pages 1989 - 1993 | - BANG H; EGERER K; GAULIARD A; LUTHKE K; RUDOLPH PE; FREDENHAGEN G ET AL., "Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis", ARTHRITIS RHEUM, (2007), vol. 56, no. 8, pages 2503 - 2511 |